Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
Open Access
- 9 March 2017
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 163 (2) , 383-390
Abstract
Purpose Many women with an elevated risk of hereditary breast and ovarian cancer have previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a subset has hereditary susceptibility to cancer and requires further testing. We sought to identify specific groups who remain at high risk and evaluate whether they should be offered multi-gene panel testing. Methods We tested 300 women on a multi-gene panel who were previously enrolled in a long-term study at UCSF. As part of their long-term care, all previously tested negative for mutations in BRCA1 and BRCA2 either by limited or comprehensive sequencing. Additionally, they met one of the following criteria: (i) personal history of bilateral breast cancer, (ii) personal history of breast cancer and a first or second degree relative with ovarian cancer, and (iii) personal history of ovarian, fallopian tube, or peritoneal carcinoma. Results Across the three groups, 26 women (9%) had a total of 28 pathogenic mutations associated with hereditary cancer susceptibility, and 23 women (8%) had mutations in genes other than BRCA1 and BRCA2. Ashkenazi Jewish and Hispanic women had elevated pathogenic mutation rates. In addition, two women harbored pathogenic mutations in more than one hereditary predisposition gene. Conclusions Among women at high risk of breast and ovarian cancer who have previously tested negative for pathogenic BRCA1 and BRCA2 mutations, we identified three groups of women who should be considered for subsequent multi-gene panel testing. The identification of women with multiple pathogenic mutations has important implications for family testing.Keywords
This publication has 30 references indexed in Scilit:
- Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectivesBMC Bioinformatics, 2013
- A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1Journal of Medical Genetics, 2012
- Clinical significance of large rearrangements in BRCA1 and BRCA2Cancer, 2012
- Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancerBreast Cancer Research, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Accurate and exact CNV identification from targeted high-throughput sequence dataBMC Genomics, 2011
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingProceedings of the National Academy of Sciences, 2010
- Absence of the BRCA1 del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican HispanicsBreast Cancer Research and Treatment, 2009
- Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic FamiliesCancer Epidemiology, Biomarkers & Prevention, 2007
- BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patientsAnnals of Oncology, 2004